secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001140361-23-024500
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics Q1 net loss widens to $11.5M; NAVIGATE trial fully enrolled with 357 patients
--------------------------------------------------------------------------------

- Net loss of $11.5M ($0.19/shr) vs $9.9M loss in Q1 2022, driven by higher R&D costs.
- R&D expenses rose to $8.8M from $8.1M, primarily for the NAVIGATE trial.
- Cash and equivalents $17.8M; additional $40M available under chairman's line of credit.
- NAVIGATE Phase 2b/3 trial for NASH cirrhosis esophageal varices enrolled 357 patients; interim results expected Q4 2024.
- Company evaluating potential Phase 2 trial of belapectin + Keytruda in advanced head and neck cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123024500/0001140361-23-024500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123024500/brhc20052846_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-024500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer